Every material Form 8-K Atea Pharmaceuticals, Inc. has filed with the SEC since March 05, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Atea Pharmaceuticals entered a Loan and Security Agreement with Hercules Capital on November 6, 2026, providing for senior secured term loans of up to $200.0 million, with $65.0 million drawn at closing. The loans mature on November 1, 2031, and are secured by substantially all of the company's assets, including its intellectual property, which gives shareholders a larger fixed debt obligation tied to the company's development of BEM/RZR.
Tranche 1 loan of $65.0 million was drawn on the November 6, 2026 closing date; further tranches total up to $135.0 million
Interest floats at the greater of the WSJ prime rate plus 2.35% or 9.35%, paid monthly, with interest-only payments for 48 months
Tranche 2 availability depends on completing the Phase 3 trial of BEM/RZR before a specified date in the second half of 2027
Financial covenants include a minimum cash test beginning October 1, 2027, and a performance covenant tied to FDA approval of BEM/RZR
Atea Pharmaceuticals reported a narrower second-quarter net loss of $32.9 million, down from $37.2 million a year earlier, as lower research and development and general and administrative spending more than offset lower interest income. Cash and investments fell from $301.8 million at December 31, 2025 to $219.5 million at June 30, 2026. The release also restates the July C-BEYOND Phase 3 results and gives timing for C-FORWARD topline data and a planned new drug application, which shape the company's path to a possible US launch of BEM/RZR.
Net loss of $32.9 million, or $0.41 per share, for the three months ended June 30, 2026, versus $37.2 million, or $0.44 per share, a year earlier.
Research and development expenses fell to $28.2 million from $32.3 million; general and administrative expenses fell to $7.0 million from $9.1 million.
Cash, cash equivalents and marketable securities were $219.5 million at June 30, 2026, down from $301.8 million at December 31, 2025.
C-FORWARD Phase 3 topline results are expected in early first quarter 2027; a new drug application submission is anticipated in the second quarter of 2027.
Atea Pharmaceuticals reported a first-quarter 2026 net loss of $45.4 million, or $0.57 per share, up from $34.3 million, or $0.40 per share, a year earlier. Research and development spending rose to $41.1 million, driven by Phase 3 hepatitis C trial costs, and cash, cash equivalents and marketable securities fell to $256.0 million from $301.8 million at December 31, 2025. The filing reports no revenue, and the company said its two hepatitis C Phase 3 topline readouts are expected in mid-2026 and around year-end 2026.
Net loss was $45.4 million ($0.57 per share) for the three months ended March 31, 2026, versus $34.3 million ($0.40 per share) a year earlier.
Research and development expenses increased $11.6 million to $41.1 million; general and administrative expenses decreased $2.6 million to $6.9 million.
Cash, cash equivalents and marketable securities were $256.0 million at March 31, 2026, down from $301.8 million at December 31, 2025.
C-BEYOND Phase 3 topline results are expected mid-2026; C-FORWARD topline results are expected around year-end 2026.
Atea Pharmaceuticals reported a fourth-quarter 2025 net loss of $44.9 million, or $0.57 per share, up from $33.5 million, or $0.40 per share, a year earlier. For the full year, the net loss narrowed to $158.3 million, or $1.94 per share, from $168.4 million, or $2.00 per share. Cash and investments fell to $301.8 million at December 31, 2025, from $454.7 million, and the filing gives no revenue figure.
Q4 2025 research and development expenses rose to $47.8 million from $25.7 million, partly due to HCV Phase 3 spending and a milestone under the Merck License Agreement.
Full-year 2025 general and administrative expenses fell to $32.9 million from $48.8 million, mainly on lower stock-based compensation.
Income tax benefits of $6.8 million in Q4 and $6.2 million for the full year were primarily from recognition of previously unrecognized tax benefits.
C-BEYOND topline results are expected mid-2026 and C-FORWARD topline results around year-end 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Atea Pharmaceuticals, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →